A Randomized, Double-blind, Placebo-controlled Parallel Trial of Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody by Single Subcutaneous Injection in Healthy Subjects
Latest Information Update: 07 Jun 2022
At a glance
- Drugs 610 (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sunshine Guojian Pharmaceutical
Most Recent Events
- 29 Jun 2020 New trial record